



The World Anti-Doping Code

GUIDELINE FOR TUE ENQUIRIES BY ACCREDITED LABORATORIES

Version 1.0

2009

GUIDELINE for TUE ENQUIRIES BY ACCREDITED LABORATORIES

INTRODUCTION

The following guideline is the result of continuing efforts to harmonize reporting procedures based on the requirements of the *International Standard for Laboratories* version 6.0 (ISL), as well as on the observations and recommendations by the WADA Laboratory Committee and the WADA Department of Standards and Harmonization

This guideline was produced to assist the WADA-accredited laboratories in reporting Presumptive Analytical Findings (PAF) for S.3. Beta-2 Agonists and S.9. Glucocorticosteroids drug classes and enquiring about the existence of an approved Therapeutic Use Exemption (TUE). In accordance with ISL (provision 5.2.4.3.1.1) the decision to confirm or report negative findings by the results management authority (RMA) is retained by the Laboratory as part of the record. The form below is an example of how this requirement may be met. It is recommended that all WADA-accredited laboratories refer to this form when contacting RMAs for the existence of an approved TUE.

The guideline is not meant to dictate the format of Laboratory's correspondence but to serve as a guideline for the content. It can be incorporated in whole, or in part, and can be amended or reworded to best fit the needs of the Laboratory as well as those of the associated RMA(s).

It is also recognized that different wording may be required depending on any combination of legislation, policy or private law, and the needs of the RMA(s). This guideline therefore has sought to identify all the mandatory elements of the ISL, and some of the general principles important for the harmonized reporting of PAFs.

WADA thanks the WADA Laboratory Committee and the WADA-accredited laboratories for their valuable contribution in the development of this document.

TUE Enquiry Form

Date:	
Results Management Authority:	
Sample Code:	Lab Code:
Sport/Discipline:	
Mission Code/Batch ID/Event :	

Laboratory initial testing (screen) analysis of the above named sample identified a Presumptive Analytical Finding that may fall under the Therapeutic Use Exemption status within the following drug class identified in the WADA Prohibited List:

Presumptive Analytical Finding:		
Drug Class	<input type="checkbox"/> S.3. Beta-2 agonists	<input type="checkbox"/> S.9. Glucocorticosteroids
Estimated concentration¹ based on initial test:		

¹ the concentration value is a non-confirmed estimation based on a qualitative initial test result.

<i>Name and Title of responsible person:</i>	
<i>Signature:</i>	<i>Date:</i>

=====
Section below to be completed by the relevant Results Management Authority:

Please indicate below whether the Laboratory is to perform a confirmatory analysis (based on the existence or absence of a valid TUE for this substance related to the sample identified above)

<input type="checkbox"/>	Do not confirm the presumptive analytical finding and report sample negative. (An acceptable TUE/declaration of use, in compliance to the TUE Standard is on file ²).
<input type="checkbox"/>	Confirm the presumptive analytical finding and report confirmation result.

² It is the role of the Testing Authority to ensure that the nature of the substance(s) found in the sample is/are commensurate with the prescription as indicated on the granted TUE.

<i>Name and title of responsible person:</i>	
<i>Signature of responsible person:</i>	
<i>Organization:</i>	<i>Date:</i>

Please forward this completed form to the [name] Laboratory at
Fax: 123-456-7890 or email scientist@laboratory.org

WADA shall be informed at the following contact:
Results Management Fax: 514-904-4545